Renalytix plc announced an agreement with Tempus AI, Inc. to make kidneyintelX.dkd prognostic blood testing more widely available for eligible patients within Tempus's U.S. network of healthcare institutions. This collaboration aims to advance intelligent risk assessment in diabetic kidney disease.
The target patient population includes nearly 15 million individuals in the U.S. who have type 2 diabetes with chronic kidney disease. This partnership leverages Tempus's extensive network to expand access to critical diagnostic testing for a significant patient demographic.
This agreement represents an expansion of Tempus's focus beyond oncology into a new and important disease area. It demonstrates the company's ability to apply its platform and network to address unmet medical needs in broader healthcare segments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.